

Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer

NCT07393048

Status	RECRUITING
Sponsor	Beijing Friendship Hospital
Enrollment	60 participants

Plain Language Summary

This study is testing whether a blood test that detects circulating tumor DNA (ctDNA) — tiny fragments of cancer DNA released into the bloodstream — can accurately predict how well neoadjuvant (pre-surgery) treatment is working in people with rectal cancer. The test could help doctors adjust treatment plans before surgery. This is an observational study — it does not change your treatment.

****You may be eligible if...****

- You are 18 to 75 years old
- You have been diagnosed with rectal adenocarcinoma (rectal cancer) confirmed by biopsy
- Your cancer is clinical stage II or III on MRI
- Your tumor is in the lower rectum (within 10cm of the anal opening)
- Your cancer can be surgically removed
- You have not yet received any cancer treatment (no prior chemo, radiation, or surgery for this cancer)

****You may NOT be eligible if...****

- You have already received treatment for rectal cancer
- Your cancer is not surgically removable
- You have serious organ problems that prevent standard treatment
- You are pregnant or breastfeeding

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (12)

- : Signed a written informed consent form and voluntarily participated in this study
- : Aged 18-75 years, regardless of sex
- : Histopathologically confirmed rectal adenocarcinoma
- : Clinical stage II-III as assessed by MRI (according to the AJCC 8th edition)
- : Distance from the lower tumor margin to the anal verge ≥ 10 cm
- ... and 7 more (see full listing online)

Exclusion (8)

- : History of allergy to monoclonal antibodies, any component of tislelizumab, or capecitabine
- : Prior or ongoing receipt of any tumor-directed surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc
- : Presence of any active autoimmune disease or history of autoimmune disease
- : History of immunodeficiency, including a positive HIV test result, other acquired or congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation

<https://clinicaltrials.gov/study/NCT07393048>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- : Poorly controlled cardiac clinical symptoms or diseases, including but not limited to: heart failure of NYHA class II or above, unstable angina, myocardial infarction within the past year, or clinically significant supraventricular or ventricular arrhythmia that remains poorly controlled without or despite clinical intervention

... and 3 more (see full listing online)

Locations (1 total)

Beijing Friendship Hospital, Beijing, Beijing Municipality, China

<https://clinicaltrials.gov/study/NCT07393048>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.